Literature DB >> 25398955

Payment for oncolytics in the United States: a history of buy and bill and proposals for reform.

Blase N Polite1, Jeffery C Ward2, John V Cox1, Roscoe F Morton1, John Hennessy1, Ray D Page1, Rena M Conti1.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25398955      PMCID： PMC4223709          DOI： 10.1200/JOP.2014.001958

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  12 in total

1.  Innovation and The Welfare Effects of Public Drug Insurance.

Authors:  Darius Lakdawalla; Neeraj Sood
Journal:  J Public Econ       Date:  2009-04-01

2.  International prices and availability of pharmaceuticals in 2005.

Authors:  Patricia M Danzon; Michael F Furukawa
Journal:  Health Aff (Millwood)       Date:  2008 Jan-Feb       Impact factor: 6.301

3.  Reforming the payment system for medical oncology.

Authors:  Peter B Bach
Journal:  JAMA       Date:  2013-07-17       Impact factor: 56.272

4.  Proportion of physicians in large group practices continued to grow in 2009-11.

Authors:  W Pete Welch; Alison Evans Cuellar; Sally C Stearns; Andrew B Bindman
Journal:  Health Aff (Millwood)       Date:  2013-09       Impact factor: 6.301

5.  Hospitals, market share, and consolidation.

Authors:  David M Cutler; Fiona Scott Morton
Journal:  JAMA       Date:  2013-11-13       Impact factor: 56.272

6.  National Oncology Practice Benchmark, 2012 report on 2011 data.

Authors:  Elaine L Towle; Thomas R Barr; James L Senese
Journal:  J Oncol Pract       Date:  2012-10-02       Impact factor: 3.840

7.  Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists.

Authors:  Rena M Conti; Arielle C Bernstein; Victoria M Villaflor; Richard L Schilsky; Meredith B Rosenthal; Peter B Bach
Journal:  J Clin Oncol       Date:  2013-02-19       Impact factor: 44.544

8.  Cost consequences of the 340B drug discount program.

Authors:  Rena M Conti; Peter B Bach
Journal:  JAMA       Date:  2013-05-15       Impact factor: 56.272

9.  Payer management of oncology gets serious.

Authors:  Michael Snyder; Lee Goldberg; Tracey Ryan
Journal:  Am J Manag Care       Date:  2012-02       Impact factor: 2.229

10.  "Just caring": can we afford the ethical and economic costs of circumventing cancer drug resistance?

Authors:  Leonard M Fleck
Journal:  J Pers Med       Date:  2013-07-16
View more
  5 in total

1.  Diffusion of Bevacizumab Across Oncology Practices: An Observational Study.

Authors:  Nancy L Keating; Haiden A Huskamp; Deborah Schrag; John M McWilliams; Barbara J McNeil; Bruce E Landon; Michael E Chernew; Sharon-Lise T Normand
Journal:  Med Care       Date:  2018-01       Impact factor: 2.983

2.  Reform of the Buy-and-Bill System for Outpatient Chemotherapy Care Is Inevitable: Perspectives from an Economist, a Realpolitik, and an Oncologist.

Authors:  Blase Polite; Rena M Conti; Jeffery C Ward
Journal:  Am Soc Clin Oncol Educ Book       Date:  2015

3.  Trends and Disparities in Asthma Biologic Use in the United States.

Authors:  Jonathan W Inselman; Molly M Jeffery; Jacob T Maddux; Nilay D Shah; Matthew A Rank
Journal:  J Allergy Clin Immunol Pract       Date:  2019-08-28

4.  Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer.

Authors:  Aaron P Mitchell; Akriti Mishra Meza; Katherine S Panageas; Allison Lipitz-Snyderman; Peter B Bach; Michael J Morris
Journal:  J Natl Cancer Inst       Date:  2022-03-08       Impact factor: 11.816

5.  Are Small Reimbursement Changes Enough to Change Cancer Care? Reimbursement Variation in Prostate Cancer Treatment.

Authors:  Shellie D Ellis; Ronald C Chen; Stacie B Dusetzina; Stephanie B Wheeler; George L Jackson; Matthew E Nielsen; William R Carpenter; Morris Weinberger
Journal:  J Oncol Pract       Date:  2016-03-08       Impact factor: 3.840
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.